Reply: RE: Reyes A, Révil C, Niggli M, et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Curr Med Res Opin. 2019;35(12):2079-2087

Curr Med Res Opin. 2020 Jul;36(7):1129-1130. doi: 10.1080/03007995.2020.1744550. Epub 2020 Apr 7.

Affiliations

¹ F. Hoffmann-La Roche, Basel, Switzerland.
² Roche Pharma AG, Grenzach-Wyhlen, Germany.
³ Genentech, San Francisco, CA, USA.
⁴ Bridge Medical, New Delhi, India.
⁵ Certara, Lörrach, Germany (formerly Analytica Laser).

PMID: 32180474
DOI: 10.1080/03007995.2020.1744550

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Bispecific*
Antibodies, Monoclonal, Humanized
Factor VIII
Hemophilia A* / drug therapy
Humans
Network Meta-Analysis

Substances

Antibodies, Bispecific
Antibodies, Monoclonal, Humanized
emicizumab
Factor VIII